Goldman Sachs launches $650 million fund for life science investments; LabCentral, a crucial Boston incubator for drug discovery, is slated to grow amid industry slowdown

Taking stock of the drug industry, from the lab to the medicine chest

January 3, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | Goldman Sachs launches $650 million fund for life sciences investments First-time funds have been difficult to raise during the biotech downturn, but Goldman likely benefited from its recognizable name. By Allison DeAngelis STAT+ | LabCentral, a crucial Boston incubator for drug discovery, is slated to grow amid industry slowdown LabCentral, a growing feeder channel for drug discovery, has about 50 industry partners, including drugmakers such as Pfizer and Biogen. By Robert Weisman — Boston Globe STAT+ | A single drug and multiple study failures leave Anavex with nothing but cash The latest study outcome was never in doubt, so the only surprise from the readout was Anavex's lame attempt at damage control. By Adam Feuerstein

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser